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Abstract
Background: The objective of this study was to ascertain the scoring and assess the psychometric properties of
the Eye-Drop Satisfaction Questionnaire (EDSQ), a 43-item Patient-Reported Outcome instrument developed to
assess patients’ satisfaction and compliance with glaucoma treatment.
Methods: The EDSQ was administered during an observational, retrospective study to 184 French patients treated
for glaucoma. The hypothesized structure, including six dimensions (patient-clinician relationship; patient
experience; patient-treatment interaction; apprehension; patient knowledge; travel), was tested by assessing the
internal consistency reliability (Cronbach’s alpha) and construct-related validity (item convergent and discriminant
validity). As unsatisfactory results were demonstrated, another structure was defined using a principal component
analysis (PCA) combined with content of items. Psychometric properties of this new structure were assessed.
Scores were compared between low, moderate and high compliance profile groups defined using data collected
with the Travalert electronic device.
Results: Analyses were performed with the 169 patients who completed at least half of the EDSQ items. The
hypothesized structure showed a Cronbach’s alpha lower than 0.70 for four dimensions out of six and an overall
poor construct-related validity (range of item-scale correlations: 0.00-0.68). The new structure obtained with the
PCA included six dimensions: concern about treatment (five items); concern about disease (two items); satisfaction
with patient-clinician relationship (five items); positive beliefs (three items); treatment convenience (three items);
and self-declared compliance (three items). A score ranging from 0 to 100 was calculated for each dimension, with
higher scores indicating more of the attribute referred to in the dimension. Internal consistency reliability was
good (Cronbach’s alpha greater than 0.70 for five dimensions). The structure offered good construct-related validity
(range of item-scale correlations: 0.36-0.82). Ceiling effects of 21% and 49%, were observed for the satisfaction with
patient-clinician relationship and self-declared compliance scores. Patients in low compliance profile group
reported the lowest score for the satisfaction with patient-clinician relationship, positive beliefs, treatment
convenience and self-declared compliance dimensions, and the highest score for the concern about treatment
dimension.
Conclusions: The scoring of the EDSQ was developed and the questionnaire proved to have satisfactory
psychometric properties. EDSQ scores showed a promising relationship to compliance profiles. The EDSQ could be
used in future studies.
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Glaucoma is a group of conditions that damage the
eye’s optic nerve, causing progressive loss of sight. A
higher intra-ocular pressure has been found to be asso-
ciated with an increased risk of glaucoma. Glaucoma is
the second most common cause of worldwide blind-
ness after cataracts[1]. The most common type of glau-
coma is Primary Open Angle Glaucoma (POAG), with
the only noticeable sign being the gradual loss of
vision. Treatments of POAG are aimed at reducing the
intraocular pressure (IOP) and include mainly topical
therapy, even if other treatments such as surgery or
laser can be used for the most severe cases. Treat-
ments are used to slow or prevent the disease progres-
sion as glaucoma cannot be totally cured and damage
caused cannot be reversed[2]. As patients do not
experience any symptoms and as POAG is an irreversi-
ble condition, the benefit of treatment is not directly
perceived by the patient. In addition, patients treated
with eye drops are confronted with many constraints,
including the lifelong nature of the treatment, the
complexity of the treatment regimen (e.g. instillation
at set times, several eye-drop intakes per day, difficulty
in self-administration of eye-drops), and the risk of
s i d ee f f e c t ss u c ha se y ei r r i tation or eye pain. Thus the
risk of non-compliance is high[3-6], for example omis-
sion of eye-drop intake or voluntary interruption of
the treatment over a few days. Since the effectiveness
of glaucoma treatment depends on strict compliance,
management of patients should take into account the
risk of non-compliance. Compliance and its measure is
a real issue in the treatment of glaucoma[4] and fac-
tors having an impact on compliance are worthwhile
to explore. Complex dosing regimens[7] and patients’
perception and knowledge about their illness and its
treatment[8,9] have been identified as potential barriers
to compliance. Continuing such investigation may
result in the discovery of ways to improve compliance
of patients treated for glaucoma, and therefore to
improve the effectiveness of treatments.
According to theoretical satisfaction models, satisfac-
tion of individuals impacts on their subsequent beha-
viour [10]. This assertion, when translated in the
context of the uptake of a treatment, means that the
satisfaction with a treatment has an effect on patient
compliance and continuation of a treatment. In prac-
tice, higher satisfaction with a treatment has been
reported to be associated with better treatment com-
pliance in glaucoma[11,12], as well as in other chronic
diseases such as asthma[13] or diabetes[14]. Assessing
patients’ satisfaction with a glaucoma treatment is of
particular interest in the context of measurement of
patients’ compliance with glaucoma treatment.
The Eye-Drop Satisfaction Questionnaire (EDSQ) has
been developed to assess patients’ satisfaction and com-
pliance with glaucoma treatment. The development of
the conceptual framework of the questionnaire (items
and dimensions) have been published previously[15].
The objective of this paper is to present the scoring
method and the psychometric properties of the EDSQ.
Methods
Patients and study design
An observational, multicenter, cross-sectional and retro-
spective study was conducted in France with glaucoma-
specialized ophthalmologists selected from a list of
ophthalmologists prescribing the Travalert
CE device to
their patients. To be eligible for the study, patients had
to be over 18 years old and diagnosed with POAG, such
as juvenile glaucoma, exfoliative glaucoma, pigmentary
glaucoma or normal tension glaucoma, or high IOP.
Patients who were using the Travalert device for admin-
istration of treatment for at least 6 weeks and who
agreed to participate were included in the study.
Patients with secondary glaucoma (congenital glaucoma,
inflammatory glaucoma, angle-closure or narrow angle
glaucoma following cataract surgery), patients taking
non ocular treatment to be taken three times per day or
more or associated with a strong burden (e.g. anticoagu-
lant), and patients with chronic eye dryness requiring
the instillation of more than five drops a day were not
included in the study. A total of 184 patients were
enrolled in the study.
At the inclusion visit, ophthalmologists had to com-
plete a medical questionnaire for each patient, including
information about ocular and non-ocular co-morbidity,
non medical treatment of POAG/IOP (surgery or laser),
visual acuity and IOP measurement. Ocular co-morbid-
ities included age-related macular degeneration, retinal
detachment, non operated cataract, diabetic retinopathy
and uveitis; other co-morbidities included 17 common
conditions such as myocardial infarction, dementia, dia-
betes, cancers and AIDS. At this visit, patients were
asked to complete the EDSQ.
The EDSQ
The EDSQ is a self-administered questionnaire that aims
to assess patients’ satisfaction and compliance with eye-
drop treatment for glaucoma or IOP. It was developed
simultaneously in French and UK English[15]. Patient
and clinician interviews were conducted to ascertain the
conceptual model for satisfaction with eye-drop treat-
ment and to collect patients’ comments verbatim. Cog-
nitive debriefing was then conducted with French and
English patients to pre-test the questionnaire (assess-
ment of questionnaire’s clarity, ease of comprehension
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covering six hypothesized dimensions: patient character-
istics (14 items) including apprehension (three items)
and travel (three items), treatment characteristics (four
items), patient-clinician relationship (seven items),
patient experience (seven items), patient-treatment
interaction (eight items) and patient knowledge (three
items). The 43 items had different response scales: one
was continuous (age), eight were dichotomous, two were
categorical and thirty-two were ordinal, with different
response options.
Indicator of patient compliance
Patient compliance was evaluated using Travalert, an elec-
tronic device allowing the actual use of eye drops to be
assessed by reminding the patient of the times for instilla-
tion and recording information on each eye-drop dis-
pensed. The data collected with Travalert during a recent
study conducted with 10 volunteers[16] were shown to be
accurate and reproducible in terms of the date and time-
stamping mechanisms. However, the device may overesti-
mate patients’ compliance as Travalert may count drops
that were not actually instilled in the eye.
The data collected with Travalert in the present study
were used to categorize patients into three compliance
profiles: high compliance, moderate compliance and low
compliance. This categorization was performed using
statistical clustering methods. The results have been
described in more detail elsewhere[17]. Among the 184
patients included in the study, 113 had enough data
from the Travalert device to be classified in one of the
three compliance profiles.
Statistical analyses
Analysis population
Analyses were performed for all patients with an asses-
sable EDSQ, that is, with at least 50% of the 43 EDSQ
items completed. Age groups were defined using terciles
resulting from the description of age in the analysis
population.
Scoring of the EDSQ
The quality of completion was analysed on all EDSQs
received. The first structure tested was composed of six
scores with 27 ordinal items, based on the EDSQ
hypothesized structure: patient-clinician relationship (five
items), patient experience (seven items), patient-treat-
ment interaction (six items), patient knowledge (three
items), apprehension (three items) and travel (three
items). The items not included in this structure were not
used for the analyses. In particular, the items about
patient demographics and the items about treatment
characteristics (e.g. number of instillations per day or
time of instillation) were not included since a
unidimensional concept could not be hypothesized for
them. The psychometric properties of the hypothesized
structure, including the internal consistency reliability
and construct-related validity, were tested. Reliability
coefficients of the scores (i.e. ratio of variance in true
scores to the variance in observed scores) were estimated
using Cronbach’s coefficient alpha. Cronbach’sa l p h a
assesses internal consistency reliability and is calculated
from the correlations among items included in a score
and the number of items in the score. It ranges from 0 to
1, with a recommended threshold of 0.70[18]. The con-
struct-related validity was determined by assessing the
item convergent validity (the correlation of an item with
its own dimension should be higher than 0.40) and item
discriminant validity (the correlation of an item with its
own dimension should be higher than with all the other
dimensions). The percentage at floor, i.e. the percentage
of patients reporting the lowest possible score, and the
percentage at ceiling, i.e. the percentage of patients
reporting the highest possible score were also described.
Unsatisfactory results were found for the hypothesized
structure. Therefore, a second structure was defined on
the same 27 items using a principal component analysis
(PCA) with Varimax rotation. An orthogonal rotation
was preferred to an oblique rotation (e.g. Promax)
because the content variety of EDSQ items entailed the
creation of scores as independent as possible. The selec-
tion criterion for dimensions was eigenvalues greater
than one. Items were retained in the factor for which
they had the highest loading greater than 0.40. The PCA
was applied to the 145 patients with no missing data for
the 27 items included in the analysis. The psychometric
properties of this new structure were tested in a similar
way as for the hypothesized structure.
The EDSQ scores were calculated using the factor
structure resulting from the PCA, with each item contri-
buting equally to the score, and linearly transformed to
a 0-100 scale as follows: (mean of item scores - 1) × 25.
Description of EDSQ scores
The description of the final EDSQ scores was performed
on the overall analysis popul a t i o n ,a sw e l la sb yg e n d e r
and by age group. The EDSQ scores were also described
according to the compliance profiles of patients defined
from the Travalert classification.
Statistical tests, level of significance and software
A Mann-Whitney-Wilcoxon test was used to compare a
continuous variable between two groups of patients, and
a Kruskal-Wallis test was used to compare a continuous
variable between more than two groups of patients. The
threshold for statistical significance was fixed at 5%. All
analyses were performed using SAS® software for Win-
dows (SAS v9.1; SAS Institute, Inc., Cary, NC, USA).
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Description of patients’ characteristics
Among the 184 patients included in the study, 169 com-
pleted at least 50% of the EDSQ items and were
included in the analysis population. The mean age was
65 years (Table 1). There was a balanced number of
males and females (83 and 85, respectively), with most
patients being retired and not living alone (61% and
78%, respectively). A minority of patients (11%) had an
ocular co-morbidity and 30% had a non-ocular co-mor-
bidity; 17% had had surgery for POAG or IOP and 10%
had been treated by laser. At the inclusion visit, the
mean IOP was 16.42 mm Hg for the worse eye, and the
median visual acuity for the best eye was 10 (decimal).
The classification based on data collected with the Tra-
valert device categorized the majority of patients in the
“high compliance” group (57%), while 21% were in the
“moderate compliance” group and 22% in the “low com-
pliance” group.
Quality of completion and distribution of item scores
On average 1.3% of the item responses were missing;
79% of patients did not have any missing items. The
item with the highest number of missing data was the
item about the number of different ophthalmic drops
taken daily (4.1%).
For 23 of the 30 EDSQ items with an ordinal response
scale, most patients used one of the two most favourable
response categories. Indeed, the majority of patients
answered the most favourable response choices for the
items about their satisfaction (e.g. “very” or “extremely”
to satisfaction with care, satisfaction with information,
and treatment convenience), their compliance (e.g.
“always” to self-declared compliance over the last 4
weeks, “never” to default in instillation of eye drops in
general), and the nuisance of treatment (e.g. “n o ta ta l l ”
to concern about putting things into one’se y e sa n d
blink reflex).
Ascertaining the scoring of the EDSQ
For the hypothesized structure including 27 items,
Cronbach’sa l p h a sr a n g e df r o m0 . 3 8f o rt h et r a v e l
dimension to 0.73 for the patient experience dimension
(Table 2). All items of the apprehension dimension and
almost all items of the patient knowledge dimension
met the convergent and discriminant validity criteria.
For the patient-clinician relationship, patient experience,
patient-treatment interaction and travel dimensions,
80%, 57%, 33% and 67% of the items, respectively, met
the convergent validity criterion, and 85%, 79%, 71% and
67% of the items, respectively, met the discriminant
validity criterion. A floor effect was observed for the
Table 1 Demographics, clinical characteristics and compliance profile of patients included in the analysis population
(N = 169)
Analysis population (N = 169)
Age (MD = 1) Mean (STD) 65.1 (11.8)
Median (range) 67.5 (18-89)
Gender, n (%) (MD = 1) Male 83 (49.1)
Female 85 (50.3)
Professional status, n (%) (MD = 1) Working full-time 37 (21.9)
Working part-time 13 (7.7)
Retired 103 (61.0)
Unemployed 3 (1.8)
House 12 (7.1)
Patient living alone, n (%) (MD = 1) No 131 (77.5)
Yes 37 (21.9)
Comorbidities, n (%) (MD = 1) Ocular 19 (11.2)
Other 50 (29.6)
Nonmedicated treatment of POAG/IOP, n (%) (MD = 1) Surgery 28 (16.6)
Laser 17 (10.1)
IOP
a (worst eye) (MD = 5) Mean (STD) 16.42 (3.87)
Median (range) 16 (9-40)
Visual acuity
b (best eye, Decimal) (MD = 13) Median (range) 10.00 (1-12)
Compliance profiles, n (%) (MD = 56) Low compliance 25 (22.1)
Moderate compliance 24 (21.2)
High compliance 64 (56.6)
STD, Standard Deviation; MD, Missing Data; POAG, Primary Open Angle Glaucoma; IOP, Intraocular Pressure
amm Hg;
bdecimal scale.
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the lowest possible score, and a ceiling effect was
observed for the patient knowledge dimension with 30%
of patients reporting the highest possible score.
The PCA conducted on the same 27 items to define an
alternative structure for the EDSQ led to eight factors
with eigenvalues greater than one, explaining 65% of the
total variance. Among the eight factors, two were not
retained because of poor consistency in the content of
items included in each of these two factors. Thus the five
items included in these two factors were not included in
the final structure of the EDSQ. In addition, the item
about consultation frequency loaded on a factor with
items related to patients’ concern about their disease.
This content difference led to the exclusion of this item
from the final structure. However, these six items were
kept in the questionnaire to be analysed separately in
future studies. Six dimensions were then selected and
named, based on the content of the items: concern about
treatment (five items), concern about disease (two items),
satisfaction with patient-clinician relationship (five
items), positive beliefs (three items), treatment conveni-
ence (three items) and self-declared compliance (three
items). The Cronbach’s alpha of each dimension was
higher than 0.70, except for the self-declared compliance
dimension (0.65) (Table 2). All items but one ("Frequency
of voluntary break” in the self-declared compliance
dimension) met the convergent validity criterion and all
items but one ("Confidence in the effectiveness of the
treatment” in the positive beliefs dimension) met the dis-
criminant validity criterion. A ceiling effect was observed
for the satisfaction with patient-clinician relationship and
the self-declared compliance dimensions (21% and 49%,
respectively, of patients reporting the highest possible
score), and a floor effect was observed for the concern
about treatment dimension (19% of patients reporting
the lowest possible score).
The final structure of the EDSQ included six dimensions
based on 21 items (Table 3). A score was calculated for
each of the six dimensions as the mean of items in the
dimension with all items contributing equally to the score,
and was linearly transformed to a 0-100 scale. Some items
were reversed so that higher dimension scores reflected
more of the attribute referred to in the dimension (e.g.
higher concern about disease, greater satisfaction with
patient-clinician relationship). Missing items were handled
using the half-scale rule (i.e. if at least 50% of the items of
the dimension are completed, missing items are replaced
by the mean of non-missing items of the dimension;
otherwise the dimension score is set to missing).
EDSQ scores according to demographic parameters (age,
gender)
A statistically significant difference in the concern about
disease score was observed according to gender (p =
0.002), with a higher score for females (mean of 56.4 vs.
Table 2 Item convergent and discriminant validity, internal consistency reliability, and floor and ceiling effect
obtained using the hypothesized and exploratory structures of the EDSQ - Patients with complete EDSQ data (N =
145)
Dimensions No. of
items
Range of item-
scale correlations
Item convergent
validity
a (% success)
Item discriminant
validity
b (% success)
Cronbach’s
alpha
Floor
(%)
Ceiling
(%)
Hypothesized structure resulting from the development phase
Apprehension 3 0.42-0.54 100.0 100.0 0.66 28.3 0.0
Patient-clinician
relationship
5 0.10-0.68 80.0 88.0 0.65 0.0 1.4
Patient experience 7 0.12-0.62 57.1 80.0 0.73 0.7 0.0
Patient knowledge 3 0.42-0.53 100.0 93.3 0.70 0.0 30.3
Patient-treatment
interaction
6 0.08-0.51 33.3 76.7 0.56 0.0 6.9
Travel 3 0.00-0.46 66.7 66.7 0.38 5.5 0.0
Exploratory structure resulting from the PCA
Concern about treatment 5 0.45-0.64 100.0 100.0 0.78 18.9 0.0
Concern about disease 2 0.82-0.82 100.0 100.0 0.90 8.8 5.4
Satisfaction with patient-
clinician relationship
5 0.49-0.73 100.0 100.0 0.78 0.0 20.9
Positive beliefs 3 0.49-0.67 100.0 93.3 0.74 0.0 4.7
Treatment convenience 3 0.50-0.60 100.0 100.0 0.72 0.7 13.5
Self-declared compliance 3 0.36-0.46 66.7 100.0 0.65 0.0 49.3
PCA, Principal Component Analysis
aSuccess criteria: item-scale correlation greater than 0.4.
bFor each item, correlation coefficient with its own scale is compared with correlation coefficients with the other scales. Reported is the percentage of all
pairwise comparisons where the correlation of an item with its own scale is greater than correlation with the other scale.
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ference in the treatment experience score was observed
according to age group (p = 0.020), with a lower score
for patients older than 72 years (mean of 67.7 vs. 73.2
for patients between 60 and 72 years and 77.8 for
patients younger than 60 years). The other EDSQ scores
did not differ statistically between gender or age groups.
Relationships between EDSQ scores and compliance
profile
No statistically significant differences in the EDSQ
scores were observed between the three compliance
profile groups (Table 5). The satisfaction with patient-
clinician relationship score presented the highest asso-
ciation with compliance (p = 0.079). The lowest satisfac-
tion with patient-clinician relationship score was
observed for patients in the low compliance profile
group (mean of 77.7 vs. 87.5 for patients in the moder-
ate compliance profile group and 83.8 for patients in the
high compliance profile group).
Patients in the low compliance profile group reported
the lowest score for satisfaction with patient-clinician
relationship, positive beliefs, treatment convenience and
self-declared compliance dimensions (mean of 77.7,
Table 3 Scoring of the EDSQ
Dimension Included items Score calculation
a
Concerns about treatment (five items) Discomfort
Worries about putting things in eyes
Blink reflex
Treatment as a burden
Feeling about lifelong treatment
If at least three items are
available:
(Mean of item scores - 1) ×
25
Concerns about disease (two items) Fear of disease evolution
Thinking about the disease consequences
If at least one item is
available:
(Mean of item scores - 1) ×
25
Satisfaction with patient-clinician relationship
(five items)
Satisfaction with visit frequency
Satisfaction with the information given by the ophthalmologist
Frequency of information given by the ophthalmologist about eye-
pressure level
Frequency of information given by the ophthalmologist about
visual acuity
Satisfaction with care
If at least three items are
available:
(Mean of item scores - 1) ×
25
Positive beliefs (three items) Confidence in the effectiveness of the treatment
Feeling about feedback and motivation
Feeling about follow-up and motivation
If at least two items are
available:
(Mean of item scores - 1) ×
25
Treatment convenience (three items) Convenience of the delivery system in bottle opening
Convenience of the delivery system in drop dosing
Convenience of storage conditions
If at least two items are
available:
(Mean of item scores - 1) ×
25
Self-declared compliance (three items) Self-assessed compliance over the last 4 weeks
Frequency treatment is forgotten in general
Frequency of voluntary break from treatment
If at least two items are
available:
(Mean of item scores - 1) ×
25
aHigher dimension scores reflect more of the attribute implied by the name (e.g. higher concern about disease, greater satisfaction with patient-clinician
relationship).
Table 4 EDSQ mean dimension scores, overall and according to age and gender (N = 168)
Dimension Total Age Gender
<60(n = 56) 60-72 (n = 56) >72 (n = 55) p-value
a Male (n = 83) Female (n = 85) p-value
b
Concern about treatment 21.0 22.1 19.8 20.7 0.785 18.9 22.8 0.197
Concern about disease 49.6 56.5 46.1 45.8 0.082 42.5 56.4 0.002
Satisfaction with
patient-clinician relationship
83.9 84.6 84.8 82.5 0.634 86.1 82.0 0.159
Positive beliefs 68.1 67.8 70.6 66.1 0.530 69.5 66.8 0.634
Treatment convenience 72.8 77.8 73.2 67.7 0.020 72.1 73.7 0.500
Self-declared compliance 93.0 91.2 93.7 93.8 0.322 92.8 93.0 0.762
aKruskal-Wallis test;
bMann-Whitney-Wilcoxon test.
In bold: statistically significant differences at the 0.05 threshold.
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for the concern about treatment dimension (mean of
22.2). As regards the concern about disease dimension,
patients in the low compliance profile group reported a
mean score close to that of patients in the moderate
compliance profile group, which reported the highest
score for this dimension (mean of 50.0 and 51.0,
respectively).
Discussion
The EDSQ was developed to measure satisfaction and
compliance of patients with glaucoma treatment. The
aim of the present study was to create the scoring
method and to assess the psychometric properties of the
EDSQ so that the questionnaire could be used in future
studies.
The questionnaire was well accepted by patients, as
shown by a good quality of completion of the EDSQ.
The psychometric properties of the hypothesized struc-
ture of the EDSQ, which included five dimensions, were
unsatisfactory, with a weak internal consistency reliabil-
ity of most dimensions and an overall poor construct-
related validity. Thus, it was decided to define an alter-
native structure using a PCA that grouped the items
into eight factors. For two of the eight factors, no single
underlying concept was observed between the items
grouped into each of these two factors; they were there-
fore not included in the structure. For the six other fac-
tors, a single underlying concept was identified between
the items grouped into each of these six factors: five
items related to concern about treatment; two items
related to concern about disease; three items related to
positive beliefs; five items related to satisfaction with
patient-clinician relationship; three items related to self-
declared compliance; and three items related to treat-
ment convenience. A score was then calculated for each
of the six final dimensions. Some final dimensions were
close to the hypothesized ones, such as the satisfaction
with patient-clinician relationship dimension with the
patient-clinician relationships hypothesized dimension;
the concern about treatment dimension with the appre-
hension hypothesized subdimension; and the patient-
treatment relationship dimension with the treatment
convenience hypothesized dimension. The major differ-
ence between final and hypothesized dimensions was
observed for the items of the patient experience
hypothesized dimension that were scattered over several
dimensions in the final structure. The six-dimension
structure defined using the PCA presented a good con-
struct-related validity, as well as a satisfactory internal
consistency reliability. In addition, patients younger than
60 years reported more concerns about disease com-
pared with older patients, as well as women compared
with men, which could have been expected as a similar
relationship of disease-related concerns with age and
gender was already observed in several diseases such as
cancer[19,20], bowel disease[21] or diabetes[22]. The 43-
item version of the EDSQ used in our study was slightly
modified while our study was being carried out, i.e. the
wording was modified for seven items, one item was
divided into two distinct items, the response scale was
modified for one item and two items, which are not
included in the final scoring presented in this paper,
were removed. Although these modifications may result
in minor changes in future studies compared with our
results, they were made to improve the content of the
questionnaire and can be expected to improve the psy-
chometric performances of the EDSQ.
A ceiling effect was observed for the satisfaction with
patient-clinician relationship and the self-declared com-
pliance dimensions as 21% and 49%, respectively, of
patients reported the highest possible score, resulting
from a skewed distribution for items related to patients’
satisfaction and self-declared compliance. However,
those results are not surprising as acquiescent response
bias[23-25], which is the tendency to agree with items
rather than disagree, and social desirability bias[26],
which is the will to give a positive self-image to the phy-
sician, are well-known phenomena when measuring
patient satisfaction and self-declared compliance.
According to theoretical satisfaction models and
results previously reported in the literature, a relation-
ship between satisfaction and compliance was expected.
Even if no statistically significant relationship was
demonstrated in our results, a clear pattern appeared in
Table 5 Association between compliance profiles and
EDSQ dimension scores (N = 113; population
documented for compliance and EDSQ): Mean scores and
p-value using a Kruskal-Wallis test
Dimensions Compliance profile
a
Low
compliance
(n = 25)
Moderate
compliance
(n = 24)
High
compliance
(n = 64)
p-
value
Concern about
treatment
22.2 18.3 17.9 0.552
Concern about
disease
50.0 51.0 47.3 0.834
Satisfaction with
patient-clinician
relationship
77.7 87.5 83.8 0.079
Positive beliefs 65.0 65.8 70.1 0.349
Treatment
convenience
67.7 74.3 73.2 0.396
Self-declared
compliance
88.2 94.8 93.7 0.213
aCompliance profiles defined from data collected with the Travalert device.
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pliance profile groups defined using Travalert data. Even
though the probability to observe this result was very
low, patients in the low compliance profile group
reported the most unfavourable score compared with
t h em o d e r a t ea n dh i g hc o m p l i a n c ep r o f i l eg r o u p sf o r
five of the six EDSQ dimensions. This result indicated a
higher level of concern about treatment, and a lower
level of satisfaction with patient-clinician relationship,
treatment convenience, positive beliefs and self-declared
compliance for those patients than for patients consid-
ered as moderately or highly compliant. Lastly, the asso-
ciation between satisfaction and compliance appeared
more complex and was reported elsewhere[27].
We acknowledge that our study had some limitations.
T h ev e r s i o no ft h eE D S Qw eu s e di sn o tt h ef i n a lo n ea s
the questionnaire was slightly modified while our study
was being conducted, and our sample size was relatively
limited to enable the generalization of our results. It
would thus be necessary to confirm the final structure
presented in this paper using the final version of the
EDSQ and a larger sample size. The cross-sectional
design of this study did not allow the longitudinal psy-
chometric properties of the questionnaire, including test-
retest reliability and responsiveness to change over time,
to be assessed. Future longitudinal studies should there-
fore be conducted to enable these properties to be evalu-
ated. Such studies would also enable the dynamic process
linking satisfaction to compliance to be explored. Trava-
lert is limited to Travatan® and DuoTrav® and therefore
extrapolation to other products would need additional
data collection. Finally, the association between clinical
characteristics, such as the severity of visual loss and
length of time with glaucoma therapy, and satisfaction
and compliance was not analysed but could be an inter-
esting point to focus on in future studies.
Measuring patients’ compliance is a complex problem
as many methods exist to determine how well patients
follow physicians’ instructions regarding a treatment
regimen[28,29]. Subjective measures, such as the EDSQ
self-declared compliance dimension score in our study,
tend to cost less than objective measures, but also to
overestimate compliance. This is partly due to the social
desirability bias, which is consistent with the ceiling
effect observed for the EDSQ self-declared compliance
score in our study. Objective measures such as the data
collected with the Travalert electronic device, which
were used to define three compliance profiles in our
study, can monitor the number of medications taken as
well as the times that medications are taken. However,
these methods tend to overestimate compliance as
patients can use the device without actually taking the
medication. Both subjective and objective measures have
advantages and disadvantages, and no one measure has
proved to be better than the others. No gold standard
has been established for the assessment of compliance
[28,29], and therefore comparing two methods remains
difficult. However, the EDSQ self-declared compliance
score has been shown to be in line with the compliance
profiles defined using data collected with the Travalert
electronic device, which is encouraging as the power of
analyses was limited. These findings indicate that along-
side objective measures, the EDSQ could be used in
more complex and possibly prospective studies to com-
prehensively describe the relationships between patients’
perception of the disease and its treatment, their satis-
faction with the treatment, their self-declared compli-
ance and the treatment effects.
Conclusions
This study allowed a scoring method for the EDSQ to
be defined and satisfactory psychometric properties of
the questionnaire to be demonstrated. The EDSQ is a
potentially valid and reliable instrument that could be
used in future studies to assess patients’ satisfaction and
compliance with their eye-drop treatment for glaucoma
or IOP.
Copyrights
EDSQ is protected by copyright with all rights reserved
to ALCON. Do not use without permission.
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